Is BEACOPP better than ABVD?

被引：10

作者：

Cheson B.D. ^{[1
]}

机构：

[1] Georgetown University Hospital, Washington, DC 20007, 3800 Reservoir Road, N.W.

来源：

Current Hematologic Malignancy Reports | 2007年 / 2卷 / 3期

关键词：

Gemcitabine; Bleomycin; German Hodgkin Study Group; Diehl Versus; Freedom From Treatment Failure;

D O I：

10.1007/s11899-007-0022-2

中图分类号：

学科分类号：

摘要：

The majority of patients with advanced Hodgkin's lymphoma are cured with currently available therapy, such as ABVD (Adriamycin [doxorubicin], bleomycin, vinblastine, and dacarbazine). However, almost 20% of patients fail to achieve a complete remission and almost 40% relapse with prolonged follow-up. BEACOPP (bleomycin, etoposide, Adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) was developed by the German Hodgkin's Study Group to improve on standard therapy by intensifying treatment and substituting the active agent etoposide for vinblastine and dacarbazine. Promising results led to the HD9 trial, in which escalated BEACOPP was superior to COPP/ABVD (cyclophosphamide, vincristine, prednisone, procarbazine/ABVD). Nevertheless, escalated BEACOPP is myelosuppressive and is associated with an increased risk of secondary malignancies. Modifications of BEACOPP have been developed in an attempt to increase efficacy and reduce the adverse effects. Whether BEACOPP should be selected in preference to ABVD may be determined by clinical stage, patient age, and other risk factors. The answer to whether escalated BEACOPP is superior to ABVD will require the results of an ongoing randomized trial. Copyright © 2007 by Current Medicine Group LLC.

引用

页码：161 / 166

页数：5

共 31 条

[21]

Ballova V., Ruffer J.-U., Haverkamp H., Et al., A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly), Ann Oncol, 16, pp. 124-131, (2005)

[22]

Hartmann P., Rehwald U., Salzberger B., Et al., BEACOPP therapeutic regimen for patients with Hodgkin's disease and HIV infection, Ann Oncol, 14, pp. 1562-1569, (2003)

[23]

Canellos G.P., Duggan D., Johnson J., Niedzwiecki D., How important is bleomycin in the Adriamycin + bleomycin + vinblastine + dacarbazine regimen?, J Clin Oncol, 22, pp. 1532-1533, (2004)

[24]

Martin W.G., Ristow K.M., Habermann T.M., Et al., Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma, J Clin Oncol, 23, pp. 7614-7620, (2005)

[25]

Santoro A., Devizzi L., Bonfante V., Et al., Phase II study with gemcitabine in pretreated patients with Hodgkin's (HD) and non-Hodgkin's lymphomas (NHL): Results of a multicenter study [abstract], Proc Am Soc Clin Oncol, 16, (1997)

[26]

Friedberg J.W., Neuberg D., Kim H., Et al., Gemcitabine added to doxorubicin, bleomycin, and vinblastine for the treatment of de novo Hodgkin's disease: Unacceptable acute pulmonary toxicity, Cancer, 98, pp. 978-982, (2003)

[27]

Bartlett N., Niedzwiecki D., Johnson J., Et al., Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804, Ann Oncol, (2007)

[28]

Hutchings M., Loft A., Hansen M., Et al., FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma, Blood, 107, pp. 52-59, (2006)

[29]

Sanchez-Aguilera A., Montalban C., de la Cueva P., Et al., Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma, Blood, 108, pp. 662-668, (2006)

[30]

Diehl V., Brillant C., Engert A., Et al., Recent interim analysis of the HD11 trial of the GHSG: Intensification of chemotherapy and reduction of radiation dose in early unfavorable stage Hodgkin's lymphoma [abstract], Blood, 106, (2005)

← 1 2 3 4 →